Table 1.
Patient characteristics and treatment outcomes
| Case | Sex | Age (years) | Prior treatment within 3 months | Combined anti-VEGF | Additional treatment | BCVA (logMAR) | CRT (μm) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6–12 weeks | 12–24 weeks | baseline | 6 weeks | 12 weeks | 24 weeks | baseline | 6 weeks | 12 weeks | 24 weeks | |||||
| 1 | M | 56 | STTA | – | – | PC | 0.16 | 0.16 | 0.22 | 0.22 | 389 | 335 | 317 | 295 |
| 2 | F | 80 | STTA, Anti-VEGF | – | PC | – | 0.22 | − 0.08 | 0.10 | 0.10 | 354 | 333 | 304 | 288 |
| 3 | M | 79 | STTA, Anti-VEGF | – | PC | PC Anti-VEGF | 0.16 | 0.16 | 0.22 | 0.22 | 350 | 372 | 420 | 309 |
| 4 | F | 75 | – | – | PC | PC | 0.3 | 0.05 | 0.05 | 0 | 524 | 530 | 431 | 294 |
| 5 | M | 81 | STTA | – | – | – | 0.22 | 0.16 | 0.16 | 0.30 | 441 | 385 | 360 | 356 |
| 6 | F | 81 | Anti-VEGF | – | – | – | 0.16 | 0.16 | 0.16 | 0.16 | 384 | 318 | 304 | 304 |
| 7 | M | 76 | Anti-VEGF | + | PC Anti-VEGF | – | 0.30 | 0.22 | 0.22 | 0.05 | 393 | 330 | 334 | 307 |
| 8 | F | 72 | Anti-VEGF | + | – | – | 0 | 0 | 0 | 0 | 383 | 212 | 215 | 254 |
| 9 | M | 74 | Anti-VEGF | – | PC Anti-VEGF | PC | 0.30 | 0.30 | 0.30 | 0.40 | 371 | 375 | 316 | 491 |
| 10 | M | 57 | – | – | – | – | − 0.08 | − 0.08 | − 0.08 | − 0.08 | 333 | 262 | 262 | 259 |
| 11 | M | 70 | STTA, Anti-VEGF | – | – | – | 0.22 | 0.30 | 0.30 | 0.30 | 432 | 325 | 324 | 289 |
| 12 | M | 64 | – | + | – | – | 0.1 | 0 | N.A. | 0 | 464 | 304 | N.A. | 302 |
BCVA, best-corrected visual acuity; logMAR, logarithm of the minimum angle of resolution; CRT, central retinal thickness; VEGF, vascular endothelial growth factor; STTA, sub-Tenon’s triamcinolone acetonide injection; PC, photocoagulation